ArticleAddiction neuroscience2023
Towards neuromarkers for tailored smoking cessation treatments.
Article in Addiction neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial.Addiction (Abingdon, England) · 2026Trial
- Attentional bias toward emotional and cigarette cues: Insights from a computer mouse-tracking task in adults who smoke and adults who do not smoke.Drug and alcohol dependence · 2026Article
- Article
- Altered Brain Dynamics in Heavy Smokers Revealed by Dynamic Functional Network Connectivity Analysis.Brain topography · 2026Article
- The late positive potential predicts contingency management outcomes for cocaine use disorder.Drug and alcohol dependence · 2025Article
- Parietal cortex is recruited by frontal and cingulate areas to support action monitoring and updating during stopping.NeuroImage · 2025Article
- Beneath the Surface of Self-Reports: Dissecting Subjective and Neural Responses to Age-Specific Visual Stimuli.Psychophysiology · 2025Article
- EEG might be better left alone, but ERPs must be attended to: Optimizing the late positive potential preprocessing pipeline.International journal of psychophysiology : official journal of the International Organization of Psychophysiology · 2024Article
- Clustering computer mouse tracking data with informed hierarchical shrinkage partition priors.Biometrics · 2024Article
- Advancing Biomarkers for Treatment of Smoking and Nicotine Dependence: An Overview.Addiction neuroscience · 2023Article
- Individual differences in late positive potential amplitude and theta power predict cue-induced eating.Addiction neuroscience · 2023Article
- Neuroaffective reactivity profiles are associated with vulnerability to e-cigarette use.Drug and alcohol dependence · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Vulnerability to compulsive drug use stems from dysregulated activity within the neural networks that underlie reward and executive functions. Empirical evidence suggests that a) attributing high motivational salience to drug-related stimuli leads to compulsive drug seeking and b) cognitive control deficits lead to compulsive drug taking. Noninvasive neuroimaging techniques enable brain activity monitoring during affective and cognitive processing and are paving the way to precision medicine for substance use disorders. Identifying robust neuromarkers of affective and cognitive dysregulation would allow clinicians to personalize treatments by targeting individual psychophysiological vulnerabilities. However, methodological choices have biased the field toward experimental paradigms that cannot optimally assess individual differences in the motivational salience of drug-related cues and in the ability to control drug-related decisions, choices which have hindered the identification of clinically relevant neuromarkers. Here, we show that once these shortcomings are amended, replicable neuromarkers of the tendency to attribute motivational salience to drug-related cues and the ability to control drug-related decisions emerge. While we use tobacco use disorder as a model, we also show that the methodological issues highlighted here are relevant to other disorders characterized by maladaptive appetitive behaviors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.